SCION: SABR and Checkpoint Inhibition of NSCLC

Summary

The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer. The purpose of the trial is to investigate whether it is safe and effective to combine standard radiation treatment with a drug called durvalumab, a type of immunotherapy. In addition, the study will use a blood test to look for cancer cell DNA to determine how long treatment with durvalumab should last. Both the use of durvalumab and the use of the blood test are new strategies for managing early stage non-small cell lung cancer.

Timeline

Start

2023-08-11

Primary completion

2026-12

Completion

2027-06

Outcome

Outcome not reported

Stopped: “Overestimated pool of eligible patients and the potential participants either declined participation or did not meet eligibility criteria.”

Drugs

Indications